Sareum Holdings plc Annual Report and Accounts 2017
a novel Chk1 inhibitor, licensed for clinical development and 
£1.50 million received from Sierra Oncology as the Company’s 
11 Directors and Company Information
22  Company Statement 
23 Company Cash Flow Statement
Annual Report and Accounts 2017 2 Drug development pipeline
The Company 
candidate is in preclinical development funded by Sareum’s Chinese 
Annual Report and Accounts 2017 3 Sareum made important progress during the year ended 
The Company ended the year with net assets of £2.34 million 
made across the Company’s programmes during the period.
development programme with SRA737 that Sierra Oncology is 
programme was licensed for further clinical development 
Annual Report and Accounts 2017 6 In addition, Sierra Oncology is evaluating SRA737, with potential 
With Sierra Oncology now funding the development 
The Company is also investigating the potential of its TYK2 inhibitors 
The Company expects to select a candidate for further development 
candidate is in preclinical development, funded by Sareum’s 
Annual Report and Accounts 2017 7 Sareum operates a lean business model to deliver the most productive return 
companies
Sareum’s co-development 
Annual Report and Accounts 2017 8 Sareum’s strategy is to develop programmes to late preclinical 
Annual Report and Accounts 2017 10 Sareum Holdings plc  
Directors and Company Information
The Directors present the Strategic report of the Company 
The Group will continue to develop its oncology programmes 
of the Company’s TYK2 inhibitors as cancer therapeutics will be 
The Directors present their report with the financial statements 
of the Company and the Group for the year ended 30 June 2017.
The Group undertakes research and development on its cancer 
report, the Report of the Directors and the financial statements in 
Company law requires the Directors to prepare Group and Company 
financial statements for each financial year.
Directors have elected to prepare the Group and Company financial 
statements in accordance with International Financial Reporting 
Under company 
law the Directors must not approve the financial statements unless 
of affairs of the Company and the Group and of the profit or loss 
time the financial position of the Company and the Group and 
the assets of the Company and the Group and hence for taking 
of the corporate and financial information included on the Company’s 
Financial statements are published on the Company’s 
The interests in the share option schemes of the Directors who served during the year were as follows:
We have audited the financial statements of Sareum Holdings plc 
(the Parent Company) and its subsidiaries (the Group) for the year 
Consolidated and Company Cash Flow Statements and related notes 
Company financial statements, as applied in accordance with the 
the Group financial statements have been properly prepared in 
the Parent Company financial statements have been properly 
the Directors have not disclosed in the financial statements 
and the Report of the Directors, but does not include the financial 
and the Report of the Directors for the financial year for 
the Parent Company financial statements are not in 
In preparing the financial statements, the Directors are responsible 
Our responsibilities for the audit of the financial statements
The financial statements were approved by the Board of Directors on 18 October 2017 and were signed on its behalf by: 
The financial statements were approved by the Board of Directors on 18 October 2017 and were signed on its behalf by: 
Company Cash Flow Statement
The consolidated financial statements of Sareum Holdings plc and its subsidiaries (the Group) have been prepared in accordance with 
However, consolidated financial statements for the financial years presented would be no different 
The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company 
Control is achieved where the Company has the power to govern the financial and operating 
Current taxes are based on the results shown in the financial statements and are calculated according to local tax rules, using tax rates 
The Group has in place a share option scheme for employees, which allows them to acquire shares in the Company.
are considered to be research and development costs and equity-settled share-based payments.
At the date of authorisation of these financial statements, the following standards and interpretations relevant to the Group that have 
financial statements of the Group.
No standards or interpretations adopted in the year had any material impact on the financial statements of the Group.
Fees payable to the Company’s auditor for the audit of the annual accounts:
Tax credit to the Income Statement (47,423) (152,565) Sareum Holdings plc  
The parent company’s loss for the financial year was £81,736 (2016: £1,048,491).
As the Group generated a loss for the year to 30 June 2016, there was no dilutive effect in respect of share options.
The associate has been accounted for using the equity method in the consolidated financial statements.
programme was licensed by the partnership to Sierra Oncology, Inc. and the partnership returned £228,977 to Sareum in respect of 
Company
At the balance sheet date the Company owned 100% of the issued ordinary share capital of Sareum Limited (the subsidiary).
is included within the consolidated financial statements of Sareum Holdings plc.
Company
Company
The Group’s principal financial instruments are trade and other receivables, trade and other payables, and cash.
The major financial risks faced by the Group, which remained unchanged throughout the year, are interest rate risk, foreign exchange 
The value of the Group’s financial instruments is not considered to be materially sensitive to the above risks and therefore no sensitivity 
Details of share options granted can be found in note 23 to the financial statements, Share-based payment transactions.
Share-based compensation reserve Cumulative fair value of share options granted and recognised as an expense in the Income Statement.
The ultimate holding company of the Group is Sareum Holdings plc.
Profit/(loss) for the financial year 400,343 (1,048,118)
Company
based on share price performance for companies operating in a similar field.
Company
Group Company
No provision has been made in the Group’s accounts and the amounts not provided for at the end of the year are as follows: